SWOG clinical trial number
SWOG-9300
A Randomized Phase II Evaluation of All Trans-Retinoic Acid (ATRA) with Interferon-Alfa 2a (IFN-alfa 2a) or All Trans-Retinoic Acid with Hydroxyurea (HU) in Patients with Newly Diagnosed Chronic Myelogenous Leukemia in Chronic Phase
Closed
Phase
Accrual
95%
Research committees
Leukemia
Treatment
Hydroxyurea
All trans retinoic acid
Interferon alpha 2a
Eligibility Criteria Expand/Collapse
Pathological diagnosis of CML in chronic phase, Ph1+, no prior therapy for CML other than hydroxyurea and/or leukopheresis of < 3 wks total duration within last 3 months, PS 0-1.
Other Clinical Trials
SWOG Clinical Trial Number
S2504
A Randomized Phase III Study of PIRtobrutinib plus R-CHOP vs. R-CHOP for Patients with Previously UntreateD RIchter TrAnsforMation (RT) (pirAMID)
Research Committee(s)
Leukemia
Lymphoma
Activated
06/01/2026
Accrual
0%
Open
Phase
SWOG Clinical Trial Number
CTSU/A042302
Phase III Evaluation of Fixed Duration Zanubrutinib Plus Sonrotoclax-Based Therapy Compared to Continuous Zanubrutinib in Previously Untreated Older Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Research Committee(s)
Leukemia
Activated
03/06/2026
Open
Phase
SWOG Clinical Trial Number
S1925
A Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia (CLL): EVOLVE CLL Study.
Research Committee(s)
Leukemia
Lymphoma
Symptom Management and Survivorship
Activated
12/14/2020
Accrual
83%
Open
Phase